U.S. Food and Drug Administration
-
Philip Morris International Enters Tender Period with Vectura Shareholders Following Unanimous Recommendation by Vectura Board
– The Vectura board have unanimously recommended PMI’s 165p-per-share offer to shareholders – The board cited PMI’s superior cash price…
Read More » -
Philip Morris International Acquires Inhaled Drug Specialist OtiTopic; Growing Pipeline of “Beyond Nicotine” Inhaled Therapeutic Products
PMI’s expertise and Beyond Nicotine portfolio companies to speed ASPRIHALE® to market LAUSANNE, Switzerland–(BUSINESS WIRE)–Philip Morris International Inc. (PMI) (NYSE:…
Read More » - Health
Takeda Presents Positive Results For Mobocertinib in Patients with EGFR Exon20 insertion+ mNSCLC Who Received Prior Platinum-based Chemotherapy
Osaka, Japan & Cambridge, Mass., United States: Mobocertinib, an oral targeted therapy, demonstrated clinically meaningful responses, with a confirmed objective…
Read More » - Health
U.S. FDA Approves Supplemental New Drug Application for Takeda’s ICLUSIG® (ponatinib) for Adult Patients with Resistant or Intolerant Chronic-Phase CML
Osaka, Japan & Cambridge, Mass., United States: – Updated ICLUSIG Label will Prove Practice-Changing, Expanding Indication to CP-CML Patients with Resistance…
Read More » - United States
Philip Morris International Announces U.S. Food and Drug Administration Authorization of IQOS 3 for Sale in the United States
New York, United States: The U.S. Food and Drug Administration (FDA) today confirmed that IQOS 3, Philip Morris International’s electrically heated…
Read More » -
New Phase 3 Data Show TAK-620 (maribavir), an Investigational Drug for the Treatment of Transplant Recipients with Refractory/Resistant Cytomegalovirus (CMV) Infections, Meets Primary Endpoint
Osaka, Japan: Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced top-line results from the Phase 3 clinical trial evaluating the…
Read More » - India
Rhizen Pharmaceuticals Announces US FDA Acceptance of its IND Application for RP7214 in SARS-CoV-2 Infection; Phase 1 Clinical Trial of RP7214 Set to Begin Early December 2020
LA CHAUX DU FONDS, Switzerland: Rhizen announces the approval of its IND by USFDA for its oral DHODH inhibitor for…
Read More » - Business
Octapharma announces FDA approval of updated NUWIQ® Prescribing Information to include immunogenicity data in previously untreated patients
LACHEN, Switzerland: Octapharma is pleased to announce that the U.S. Food and Drug Administration (FDA) has approved an updated Prescribing…
Read More »